AstraZeneca

AstraZeneca (AZN) Share Price: What to Know Before London Market Opens on 17 November 2025

As the London Stock Exchange reopens on Monday, 17 November 2025, AstraZeneca PLC (LSE: AZN, Nasdaq: AZN) is one of the most important stocks to watch. The pharma giant has just delivered forecast‑beating Q3 results, hit fresh record highs, secured shareholder backing for an upgraded New York listing and kept its drug pipeline buzzing with new data and approvals – all while navigating political noise on drug pricing in both the US and UK. Cision News+3Reuters+3Reuters+3 Below is a concise pre‑market briefing to help you understand where the AstraZeneca share price stands going into the 17 November session and what

16 November 2025

London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

UK stocks today (6 Nov 2025): FTSE 100 edges lower before BoE decision; Sainsbury lifts profit guidance, ITV warns on Q4 ads, AstraZeneca beats

LONDON — Thursday, 6 November 2025 At a glance Market snapshot: waiting on Threadneedle Street UK equities were fractionally lower by late morning, with traders staying cautious ahead of the Bank of England’s midday decision and press conference. The FTSE 100 drifted as much as about 0.3%, while sterling hovered near recent lows against major peers amid growth concerns and budget uncertainty later this month. Reuters+1 Fresh data reinforced the slowdown narrative: the S&P Global/CIPS Construction PMI fell to 44.1 in October (from 46.2), marking the fastest drop in activity since May 2020 and the longest downturn since the financial

6 November 2025

Earnings Reports · Economic News · FTSE 100 · Market Trends · NYSE:AZN · NYSE:DEO · NYSE:SNN · UK Stocks

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicines marketbeat.com astrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S. astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billion astrazeneca.com, driven by top-selling drugs like Tagrisso (lung cancer), Lynparza (ovarian cancer), Farxiga (diabetes), and Symbicort (asthma) marketbeat.com. In its 2024 Annual Report, AZN describes itself as a global, science-led, patient-focused pharmaceutical business” and targets

11 October 2025

Analyst Insights · Business News · Investment · Pharmaceuticals · Stock Market